Aura Biosciences, Inc.AURANASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank40
3Y CAGR-28.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-28.1%/yr
Annual compound
Percentile
P40
Within normal range
vs 3Y Ago
0.4x
Contraction
Streak
2 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2024 | 14.65% |
| 2023 | 51.37% |
| 2022 | 67.87% |
| 2021 | 39.46% |
| 2020 | -5.58% |
| 2019 | 0.00% |